Medicaments: containing alkaloids or their derivatives, containing pseudoephedrine (INN) or its salts, for therapeutic or prophylactic uses, packaged for retail sale

In 2024, medicaments: containing alkaloids or their derivatives, containing pseudoephedrine (inn) or its salts, for therapeutic or prophylactic uses, packaged for retail sale trade exhibited strong growth, with global flows reaching $291,860,750 and a three-year compound annual growth rate of +16.9% (five-year: +4.6%). The all-time peak of $291,860,750 was recorded in 2024.

Over the 30-year observation window (1995–2024), 69% of years recorded positive growth, indicating a predominantly expanding market. Trend momentum is strengthening (+14.0% acceleration).

The supply side is diversified (Herfindahl-Hirschman Index 0.089). The three largest exporters — France ($61.1M), Germany ($35.5M), and Switzerland ($33.4M) — collectively dominate supply flows. The leading exporter has grown at +19.8% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.036). The three largest import markets are Poland ($22.9M), United States ($21.9M), and Switzerland ($21.0M). The largest importing market sources from 10 different supplying countries.

The dominant trade corridor is Italy → Switzerland at $17.8M, representing 84.9% of the importer's total demand.

The volatility score for medicaments: containing alkaloids or their derivatives, containing pseudoephedrine (inn) or its salts, for therapeutic or prophylactic uses, packaged for retail sale is 16 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, strong demand tailwinds create a favourable entry environment. The diversified supply landscape means many competitors but also multiple entry points and buyer relationships to target.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.